Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocotrienol-rich fraction vitamin E for NAFLD in childhood obesity
NCT05905185Phase 4Completed
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tocovid in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Universiti Kebangsaan Malaysia. Primary endpoints: Fibrosis score at 6 months, Inflammation score at 6 months and 9 more. Started Jan 2020; status: completed.
02
Drugs
tocovid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05905185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905185.